Artelo Biosciences presents interim Phase 2 CAReS data on ART27.13

Artelo Biosciences (ARTL) announced the first public presentation of the interim data from its Phase 2 Cancer Appetite Recovery Study evaluating ART27.13 in patients with cancer anorexia-cachexia syndrome. The data were presented by Barry Laird, Professor of Palliative Medicine, Oslo University Hospital – Radium Hospital and University of Oslo, Norway, and Chief Investigator in CAReS, at the 8th Cancer Cachexia Society Conference held September 25-27, 2025 in Turin, Italy. The CCS presentation showed the actual interim data underlying previously announced summary results of ART27.13’s potential to meaningfully impact weight gain, lean body mass, and daily activity in patients with CACS. Importantly, Professor Laird’s presentation introduced new insights from digital wearable data, which showed that patients treated with ART27.13 had greater frequency and intensity in daily activity compared to placebo, reinforcing the therapy’s potential to improve both physical outcomes and quality of life in cancer patients suffering from this debilitating condition. Weight Gain: Patients who had lost at least 5% of body weight to be included in CAReS and titrated to the highest ART27.13 dose achieved an average +6% weight gain over 12 weeks, while patients on placebo lost an additional ~5%. Lean Body Mass: Improvements in lean body mass were aligned with total weight gains, suggesting preservation or accrual of muscle, consistent with pre-clinical research with ART27.13. Activity: Digital wearable data confirmed greater daily activity metrics among treated patients compared to placebo. Safety: ART27.13 continued to exhibit a favorable safety profile, with adverse events mostly mild to moderate and no serious drug-related events reported.